The Australian and New Zealand Haemostasis Registry: Ten years of data on off-licence use of recombinant activated factor VII

Blood Transfusion

Volumn 13, Issue 1, 2015, Pages 86-101

  Zatta, Amanda ^a   McQuilten, Zoe ^a   Kandane Rathnayake, Rangi ^a,b   Isbister, James ^a,c   Dunkley, Scott ^d   McNeil, John ^a,e   Cameron, Peter ^a,f   Phillips, Louise ^a  

^a MONASH UNIVERSITY   (Australia)

^b Australian Haemophilia Centre Directors' Organisation   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e Emergency and Trauma Centre   (Australia)

^f Calembeena Consulting   (Australia)

Author keywords

Critical bleeding; Haemostasis; Haemostasis Registry; NovoSeven ; RFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; F8 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; AUSTRALIA AND NEW ZEALAND; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; INJURY; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSTETRIC HEMORRHAGE; OUTCOME ASSESSMENT; PH; PROTHROMBIN TIME; REGISTER; TRANSIENT ISCHEMIC ATTACK; UNLICENSED DRUG USE; AUSTRALIA; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; HEMORRHAGE; MORTALITY; NEW ZEALAND; SURVIVAL RATE;

ADULT; AGED; AUSTRALIA; DISEASE-FREE SURVIVAL; FACTOR VIII; FACTOR VIIIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; REGISTRIES; SURVIVAL RATE;

EID: 84922308879     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2014.0260-13     Document Type: Article

References (40)

1. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993;7:78-83.
2. Lusher J, Roberts H, Davignon G, et al. A randomized, doubleblind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4:790-8.
3. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996;26(Suppl 1):102-8.
4. Hoffmann M, Monroe DI, Roberts H. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S61-5.
5. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S115-8.
6. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114-24.
7. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
8. Phillips L, Zatta A, Schembri N, et al. Uncontrolled bleeding in surgical patients: the role of recombinant activated factor VIIa. Curr Drug Targets 2009;10:744-70.
9. Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012;2012:1-121.
10. Boffard KD, Riou B, Warren B, et al. Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-18.
11. Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of Recombinant Activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma Acute Care Surg 2010;69:489-500.
12. Lin Y, Stanworth S, Birchall J, et al. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. Can Med Assoc J 2011;183:E9-19.
13. O'Connell KA, Wood JJ, Wise RO, et al. Thromboembolic adverse events after use of recombinant human coagulation Factor VIIa. JAMA 2006;295:293-8.
14. Yank V, Tuohy C V, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for offlabel indications. Ann Intern Med 2011;154:529-40.
15. Dzik W, Blajchman M, Fergusson D, et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products - Massive Transfusion Consensus Conference 2011: report of the panel. Crit Care 2011;15:242.
16. National Health and Medical Research Council (NHMRC). Patient Blood Management Guidelines: Module 1. Critical Bleeding and Massive Transfusion. Canberra: National Blood Authority; 2011.
17. Willis C, Jolley D, McNeil J, et al. Identifying and improving unreliable items in registries through data auditing. Int J Qual Health Care 2011;23:317-23.
18. Willis C, Cameron P, Phillips L. Clinical guidelines and offlicense recombinant activated factor VII: content, use, and association with patient outcomes. J Thromb Haemost 2009;7:2016-22.
19. McQuilten Z, Barnes C, Zatta A, et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012;129:e1533-40.
20. Dutton RP, Parr M, Tortella BJ, et al. Recombinant activated Factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011;71:12-9.
21. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377:1096-101.
22. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebocontrolled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7.
23. Ponschab M, Landoni G, Biondi-Zoccai G, et al. Recombinant activated factor VII increases stroke in cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2011;25:804-10.
24. Phillips LE, McLintock C, Pollock W, et al. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009;109:1908-15.
25. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
26. Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005;36:74-9.
27. Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008;358:2127-37.
28. Diringer M, Skolnick B, Mayer S, et al. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010;41:48-53.
29. Ranucci M, Isgrò G, Soro G, et al. Efficacy and safety of recombinant activated factor VII in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 2008;143:296-304.
30. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-800.
31. Mitra B, Phillips L, Cameron P, et al. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 2010;38:671-7.
32. Willis C, Bird R, Mullany D, et al. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 2010;98:531-7.
33. Thomas GOR, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007;62:564-9.
34. Leighton BL, Wall MH, Lockhart EM, et al. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesthesiology 2011;115:1201-8.
35. Meng ZH, Wolberg AS, Monroe DMI, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose Factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-91.
36. Cameron P, Phillips L, Balogh Z, et al. The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry. Injury 2007;38:1030-8.
37. Dunkley S, Phillips L, McCall P, et al. Recombinant activated factor VII in cardiac surgery: Experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg 2008;85:836-44.
38. Mitra B, Cameron PA, Parr MJ, Phillips L. Recombinant factor VIIa in trauma patients with the 'triad of death'. Injury 2012;43:1409-14.
39. Massive Transfusion Protocol (MTP) Template. 2013. Available at: http://www.blood.gov. au/sites/default/files/documents/pbm-mtp-template-0.ppt. Accessed on 24/09/2013.
40. Flower O, Phillips L, Cameron P, et al. Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand. Blood Coagul Fibrinolysis 2010;21:207-15.